Panelists discuss how targeted therapies for immunoglobulin A (IgA) nephropathy are advancing rapidly, with promising results from trials of B-cell modulating agents that inhibit APRIL/BAFF signaling and complement pathway inhibitors that address specific steps in the 4-hit cascade.
Novel Targeted Therapies in IgA Nephropathy: Paradigm Shift Toward Pathophysiologic Mechanisms
Therapeutic Evolution
Novel targeted therapies for IgA nephropathy (IgAN) represent a fundamental shift from broad immunosuppression to precision medicine approaches that address specific pathophysiologic mechanisms within the 4-hit cascade:
First-Hit Targeted Therapies
Second-Hit Targeted Therapies
Third-Hit Targeted Therapies
Fourth-Hit Targeted Therapies
Clinical Implications
This targeted approach enables the following:
The paradigm shift toward mechanism-based therapies promises to revolutionize IgAN management, potentially modifying disease course rather than merely managing symptoms and complications. This evolution represents a significant advancement in the field of glomerular diseases more broadly.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More